Latest news with #SIGATechnologies
Yahoo
4 days ago
- Business
- Yahoo
SIGA Technologies Inc (SIGA) Q2 2025 Earnings Call Highlights: Strong Revenue and Strategic ...
Product Revenue: $79 million for Q2 2025, including $53 million from oral TPOXX and $26 million from IV TPOXX. Outstanding Orders: $26 million of IV TPOXX orders remaining as of June 30, 2025. Development Funding: $27 million in incremental funding from the U.S. government, with $14 million for manufacturing and $13 million for the pediatric program. Research and Development Revenue: $2 million for Q2 2025 and $3 million for the first half of 2025. Pretax Operating Income: $46 million for Q2 2025 and $43 million for the first half of 2025. Net Income: $35 million for both Q2 2025 and the first half of 2025. Fully Diluted Income Per Share: $0.49 for both Q2 2025 and the first half of 2025. Cash Balance: $182 million as of June 30, 2025. Debt: No debt as of June 30, 2025. Warning! GuruFocus has detected 3 Warning Sign with HALO. Release Date: August 05, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points SIGA Technologies Inc (NASDAQ:SIGA) reported significant product revenues of approximately $79 million in the second quarter of 2025, fulfilling $70 million of orders outstanding at year-end 2024. The company received commitments from the U.S. government for $27 million of incremental development funding, supporting manufacturing activities and the pediatric program. SIGA Technologies Inc (NASDAQ:SIGA) maintains a strong balance sheet with a cash balance of approximately $182 million and no debt as of June 30, 2025. The company continues to advance its strategic initiatives, including the TPOXX post-exposure prophylaxis program for smallpox and the pediatric program in partnership with BARDA. SIGA Technologies Inc (NASDAQ:SIGA) is actively engaging with international stakeholders to expand global access to TPOXX and strengthen health security frameworks. Negative Points There are approximately $26 million of remaining outstanding orders from the U.S. government, with delivery expected in 2026, indicating potential delays in revenue recognition. The EMA's Committee of Medicinal Products for Human Use (CHMP) has commenced a referral procedure for tecovirimat, raising questions about its efficacy in treating mpox, which could impact international growth plans. International orders are expected to remain lumpy, reflecting challenges in achieving consistent sales growth in global markets. The timeline for the U.S. government RFP process remains uncertain, which could affect future procurement agreements and revenue streams. The preclinical monoclonal antibody program is still in the early stages, with ongoing evaluations needed to determine the best path forward for development and manufacturing. Q & A Highlights Q: How do you plan to deploy the $13 million BARDA funding for the pediatric program, and what is the likely trial design? A: Diem Nguyen, CEO, explained that the funding will support development activities up to regulatory filings. The trial will evaluate a refined formulation of tecovirimat for pediatric use, focusing on safe and effective dosing that mirrors adult exposure levels. Q: How does the CHMP's request for additional data from the mpox trial impact your international growth plans? A: Daniel Luckshire, CFO, stated that despite the data request, SIGA is focused on expanding its international business. The company has sold $135 million of oral TPOXX to 30 countries since 2020, indicating significant international potential. Q: Do you have any clarity on the timelines for the U.S. government RFP, and what is the typical lead time between order receipt and delivery? A: Daniel Luckshire, CFO, noted that while exact timing is uncertain, SIGA is well-positioned to engage with the U.S. government. The 2018 RFP process took about six months, but future timelines could vary. Q: What is the current status of the preclinical monoclonal antibody program, and what are your plans for clinical development? A: Diem Nguyen, CEO, expressed enthusiasm for the monoclonal antibody program, which shows promise in preclinical models. SIGA is determining the best development and manufacturing path and will update on progress. Q: Can you elaborate on your international marketing efforts since taking over from Meridian? A: Daniel Luckshire, CFO, highlighted efforts to strengthen relationships globally, focusing on ensuring countries are prepared for a smallpox outbreak. Despite geopolitical instability, SIGA sees significant potential in its international business. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Globe and Mail
4 days ago
- Business
- Globe and Mail
3 Healthcare Stocks Paying the Highest Dividends of 2025
Key Points SIGA Technologies has a sky-high dividend yield that comes with a catch. Pfizer's dividend remains strong despite a looming patent cliff. Spok Holdings offers an attractive dividend and outstanding growth. 10 stocks we like better than Pfizer › The healthcare sector has long been a favorite for income investors -- and for good reason. Many healthcare stocks offer attractive dividend yields. Some stocks stand out more than others, though. Here are the three healthcare stocks paying the highest dividends in 2025. 1. SIGA Technologies SIGA Technologies (NASDAQ: SIGA) focuses primarily on developing drugs for treating orthopoxviruses. Its flagship product is TPOXX, an antiviral medication that's approved in the U.S. and Canada for treating smallpox and in Europe, Japan, and the U.K. for treating smallpox, mpox, cowpox, and vaccinia complications. The company's dividend yield is a lofty 9.29%. However, there's something investors should know about SIGA's dividend. The drugmaker doesn't pay a regular dividend but, instead, has declared special cash dividends for four consecutive years. Special cash dividends usually aren't viewed as favorably by income investors as established programs that pay dividends on a monthly or quarterly basis. The risk that a company will decide against paying a special cash dividend in the future is probably higher than the risk that a company will suspend a regular dividend. SIGA's ability to pay dividends in the future depends largely on how seriously governments perceive the threat posed by smallpox, mpox, and other orthopoxviruses. For now, the threat level is high. That probably bodes well for the company declaring a special cash dividend in 2026, but it's difficult to predict what will happen with SIGA's dividend beyond then. 2. Pfizer Pfizer (NYSE: PFE) is the most well-known of the high-paying healthcare dividend stocks on this list. The company was founded in 1849. Today, it's one of the biggest drugmakers on the planet, with a market cap of over $130 billion and a lineup that includes multiple blockbuster drugs. Income investors have a lot to like about Pfizer. Its forward dividend yield stands at 7.32%. The company has paid a dividend for 346 consecutive quarters and has increased its dividend for 16 consecutive years. Its management team remains committed to sustaining and growing the dividend. Pfizer faces some challenges that could limit how much it's able to increase the dividend over the next few years, though. By the end of 2028, the company will lose patent protection for kidney cancer drug Inlyta, autoimmune disease drug Xeljanz, blood thinner Eliquis, breast cancer drug Ibrance, prostate cancer drug Xtandi, rare-disease franchise Vyndaqel/Vyndamx, and Mektovi, which treats melanoma and non-small cell lung cancer. While this patent cliff admittedly looks daunting, Pfizer's dividend shouldn't be in danger. The drugmaker has several rising stars, including migraine therapy Nurtec ODT and cancer drugs Padcev, Lorbrena, and Elrexfio. Pfizer's pipeline is also loaded with promising candidates, including 30 late-stage programs. 3. Spok Holdings Spok Holdings (NASDAQ: SPOK) specializes in healthcare communication and collaboration solutions. The company's flagship product, Spok Care Connect, is a unified communication platform that provides closed-loop communication, secure messaging, and collaboration capabilities to clinical teams. While Spok mainly focuses on hospitals, it also sells products to large government agencies, public-safety institutions, academic institutions, and other commercial customers. There's good news and bad news with Spok's dividend. First, the bad news: Don't expect dividend increases. Spok hasn't increased its dividend since 2022. The good news, though, is that the dividend is attractive, with a forward yield of 6.75%. Want more good news? Spok's business is booming. The company's earnings jumped 33% year over year in the second quarter of 2025. Its software operations bookings were 34% higher than the prior-year period. Unsurprisingly, Spok's stock has also performed well and is handily beating the market so far this year. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025
Yahoo
4 days ago
- Business
- Yahoo
3 Healthcare Stocks Paying the Highest Dividends of 2025
Key Points SIGA Technologies has a sky-high dividend yield that comes with a catch. Pfizer's dividend remains strong despite a looming patent cliff. Spok Holdings offers an attractive dividend and outstanding growth. 10 stocks we like better than Pfizer › The healthcare sector has long been a favorite for income investors -- and for good reason. Many healthcare stocks offer attractive dividend yields. Some stocks stand out more than others, though. Here are the three healthcare stocks paying the highest dividends in 2025. 1. SIGA Technologies SIGA Technologies (NASDAQ: SIGA) focuses primarily on developing drugs for treating orthopoxviruses. Its flagship product is TPOXX, an antiviral medication that's approved in the U.S. and Canada for treating smallpox and in Europe, Japan, and the U.K. for treating smallpox, mpox, cowpox, and vaccinia complications. The company's dividend yield is a lofty 9.29%. However, there's something investors should know about SIGA's dividend. The drugmaker doesn't pay a regular dividend but, instead, has declared special cash dividends for four consecutive years. Special cash dividends usually aren't viewed as favorably by income investors as established programs that pay dividends on a monthly or quarterly basis. The risk that a company will decide against paying a special cash dividend in the future is probably higher than the risk that a company will suspend a regular dividend. SIGA's ability to pay dividends in the future depends largely on how seriously governments perceive the threat posed by smallpox, mpox, and other orthopoxviruses. For now, the threat level is high. That probably bodes well for the company declaring a special cash dividend in 2026, but it's difficult to predict what will happen with SIGA's dividend beyond then. 2. Pfizer Pfizer (NYSE: PFE) is the most well-known of the high-paying healthcare dividend stocks on this list. The company was founded in 1849. Today, it's one of the biggest drugmakers on the planet, with a market cap of over $130 billion and a lineup that includes multiple blockbuster drugs. Income investors have a lot to like about Pfizer. Its forward dividend yield stands at 7.32%. The company has paid a dividend for 346 consecutive quarters and has increased its dividend for 16 consecutive years. Its management team remains committed to sustaining and growing the dividend. Pfizer faces some challenges that could limit how much it's able to increase the dividend over the next few years, though. By the end of 2028, the company will lose patent protection for kidney cancer drug Inlyta, autoimmune disease drug Xeljanz, blood thinner Eliquis, breast cancer drug Ibrance, prostate cancer drug Xtandi, rare-disease franchise Vyndaqel/Vyndamx, and Mektovi, which treats melanoma and non-small cell lung cancer. While this patent cliff admittedly looks daunting, Pfizer's dividend shouldn't be in danger. The drugmaker has several rising stars, including migraine therapy Nurtec ODT and cancer drugs Padcev, Lorbrena, and Elrexfio. Pfizer's pipeline is also loaded with promising candidates, including 30 late-stage programs. 3. Spok Holdings Spok Holdings (NASDAQ: SPOK) specializes in healthcare communication and collaboration solutions. The company's flagship product, Spok Care Connect, is a unified communication platform that provides closed-loop communication, secure messaging, and collaboration capabilities to clinical teams. While Spok mainly focuses on hospitals, it also sells products to large government agencies, public-safety institutions, academic institutions, and other commercial customers. There's good news and bad news with Spok's dividend. First, the bad news: Don't expect dividend increases. Spok hasn't increased its dividend since 2022. The good news, though, is that the dividend is attractive, with a forward yield of 6.75%. Want more good news? Spok's business is booming. The company's earnings jumped 33% year over year in the second quarter of 2025. Its software operations bookings were 34% higher than the prior-year period. Unsurprisingly, Spok's stock has also performed well and is handily beating the market so far this year. Should you buy stock in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Keith Speights has positions in Pfizer. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy. 3 Healthcare Stocks Paying the Highest Dividends of 2025 was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29-07-2025
- Business
- Yahoo
SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results
NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 5, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1130215. The archived webcast will be available in the Investor Relations section of the Company's website. About SIGA SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world's most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit Contacts:Suzanne Harnettsharnett@ and Investors Media Jennifer Drew-Bear, Edison GroupJdrew-bear@ Holly Stevens, CG Lifehstevens@
Yahoo
10-05-2025
- Business
- Yahoo
SIGA Technologies First Quarter 2025 Earnings: US$0.006 loss per share (vs US$0.14 profit in 1Q 2024)
Revenue: US$7.04m (down 72% from 1Q 2024). Net loss: US$408.2k (down by 104% from US$10.3m profit in 1Q 2024). US$0.006 loss per share (down from US$0.14 profit in 1Q 2024). We check all companies for important risks. See what we found for SIGA Technologies in our free report. All figures shown in the chart above are for the trailing 12 month (TTM) period Looking ahead, revenue is forecast to grow 43% p.a. on average during the next 2 years, compared to a 8.3% growth forecast for the Pharmaceuticals industry in the US. Performance of the American Pharmaceuticals industry. The company's share price is broadly unchanged from a week ago. While earnings are important, another area to consider is the balance sheet. See our latest analysis on SIGA Technologies' balance sheet health. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
